IBC Meeting Minutes

Chair- Ken Bondioli
Research Safety- Abigail Fish
Thursday, April 9, 2026
1:30 pm via Zoom

Institutions *Louisiana State University Agricultural and Mechanical College (A&M)*
Louisiana State University Ag Center

IBC Members			
	Ken Bondioli	LSU Ag Center	Chair, Animal Expert
	Abigail Fish	LSU A&M	BSO, Administrator, Voting Contact
	Sarah Keeton	LSU A&M	BSO
	Sue Hagius	LSU Ag Center	Animal Expert, Lab Rep
	Michael Hooks	LSU A&M	Member
	Jong Ham	LSU Ag Center	Plant Expert
	Christy White	Pennington Biomedical Research Center	Non-Voting Member
	Jeff Davis	LSU Ag Center	Plant and Insect Expert
	Niranjan Baisakh	LSU Ag Center	Plant Expert
	William Doerrler	LSU A&M	Member
	Ramanuj Lahiri	National Hansen's Disease Program	Member
	Rebecca Christofferson	LSU A&M	Member
	Michelle Dennis	Our Lady of the Lake Hospital	Local Non-Affiliated Member
	Brent Stanfield	LSU A&M	Member
	Ryoichi Teruyama	LSU A&M	Member
	James Bush	Blue Cross Blue Shield of Louisiana	Local Non-Affiliated Member

Members Present:	Ken Bondioli, Abigail Fish, Sarah Keeton, Sue Hagius, Michael Hooks, Ryoichi Teruyama, William Doerrler, Niranjan Baisakh, Ramanuj Lahiri, and Jong Ham.	
Members Absent:	Christy White, Michelle Dennis, Jeff Davis, Brent Stanfield, Rebecca Christofferson, and James Bush.	
Others Present:	Tolulope Omolekan	Post-Doctoral Researcher, Chamcheu Lab, Department of Pathobiological Sciences
	Jean Chamcheu	Associate Professor, Department of Pathobiological Sciences
	Udeni Balasuriya	Dr. Robert and Julia Simmons Professor, Department of Pathobiological Sciences
	Tori Coutts	Post-Doctoral Researcher, Lattin lab, Department of Biological Sciences
	Christine Lattin	Associate Professor, Department of Biological Sciences
	Morgan Kelly	Associate Professor, Department of Biological Sciences

Call to Order: 1:31 pm

Approval of Minutes from: March 12, 2026

Motion Made by:	Sue Hagius
Seconded by:	Ramanuj Lahiri
Abstaining:	William Doerrler, Niranjan Baisakh, and Jong Ham

Business and Call for New Business

Discussion of FA-TC-0201 Framework for Nucleic Acid Synthesis Screening Requirements and its impact on the IBC.

New IBC Registrations and Amendments for Review

Reg. #	PI Name	Affiliation of PI	Date Received	Title of Project	Reviewer 1	Reviewer 2
25021 (On Hold)	Udeni Balasuriya	Pathobiological Sciences	03/04/2026	Cellular Trophism and Immune Response to Bovine Herpesvirus-1	Ryoichi Teruyama	Sarah Keeton

Project Overview: This project evaluates a gene-deleted recombinant vaccine candidate for Bovine herpesvirus-1.1 (BoHV-1) . The study will compare the recombinant vaccine to both the wild-type virus and a commercially available vaccine strain to assess relative performance. Research will include laboratory-based (in vitro) studies and initial in vivo evaluations to characterize the vaccine's effectiveness and behavior. Findings from this work will support the development and assessment of improved vaccination strategies for BoHV-1.

Risk Assessment and Discussion: This project presents a moderate biosafety risk associated with work involving Bovine herpesvirus-1.1 (BoHV-1), including a gene-deleted recombinant vaccine strain, wild-type virus, and a commercial vaccine strain. The research involves in vitro laboratory studies and in vivo animal work to evaluate and compare viral strains and vaccine performance.

Potential hazards relate to handling infectious viral materials and infected animals during routine procedures, including possible exposure through direct contact, sharps use, or aerosol-generating activities. Additional risks include handling biological samples and contaminated materials. These risks are effectively managed under BSL-2/ABSL-2 and BL2-N containment through the use of biological safety cabinets for aerosol-generating procedures, appropriate PPE, standard microbiological and animal handling practices, surface decontamination, and proper waste disposal.

No significant environmental release or biosecurity concerns are anticipated. With these precautions in place, the project is considered moderate risk and appropriately contained under BSL-2/ABSL-2 and BL2-N practices.

NIH Guidelines: Section III-D-2-a
Section III-D-4-b

Biosafety Level: BSL-2, ABSL-2, and BL2-N

Training Requirements:	All personnel, including the PI, involved in this project must complete BSL-2 training in accordance with LSU's Environmental Health and Safety (EHS) and Institutional Biosafety Committee (IBC) requirements. In addition, all staff involved in animal procedures or husbandry must complete LSU's approved animal handling and species-specific training as required by the IACUC. All training must be completed before beginning work and refreshed as required by LSU policies and SOPs.
IBC Vote:	**Approved at BSL-2, ABSL-2, and BL2-N pending receipt of modifications**
Motion made by:	Ryoichi Teruyama
Seconded by:	Sarah Keeton
Abstaining:	None
Conflicts of Interest:	None

Requested Modifications:

- Section A. Project Information.
  - Personnel. Please list EHS-specific training under specific training for all personnel, including the PI.
- Section B. Project Description.
  - Procedures and Methods. Please briefly describe the procedures for immunofluorescence, western immunoblotting, and sequencing, including when potentially infectious material is inactivated. Please include a sentence on cell fixation prior to flow cytometry. Please spell out IBR and include a summary of procedures for tissue/sample processing for in vivo work.
- Section C. Risk Evaluation.
  - Biosafety. Please indicate what type of mask is required and when it must be worn. Please describe appropriate PPE for animal handlers. Please indicate which approved disinfectants are used and their required contact time.
  - Biosecurity. Please state that solid biological waste will be collected in biohazardous waste bins and sent to Stericycle for incineration.
- Section F. Recombinant DNA.
  - NIH Guidelines. Please remove Section III-D-1-a and add Section III-D-2-a and Section III-D-4-b.
- Section N. Safety.
  - BSC. Please confirm certification dates.
  - PPE. Please clarify which PPE is required and when, under Section C. Biosafety. Specifically include what is worn in the lab versus what is worn when handling animals.

Reg. #	PI Name	Affiliation of PI	Date Received	Title of Project	Reviewer 1	Reviewer 2
25069 (On Hold)	Jean Christopher Chamcheu	Pathobiological Sciences	04/01/2026	Evaluating the Anti-Tumor Efficacy of Attenuated Vesicular Stomatitis Virus and Herpes Simplex Virus-1 Strains in Psoriasis-Like Skin Inflammation in Mice	Niranjan Baisakh	Ramanuj Lahiri

Project Overview:

This project evaluates the use of attenuated viral vectors as a novel therapeutic approach for psoriasis, an inflammatory skin condition characterized by abnormal keratinocyte growth, immune dysregulation, and itchy, scaly patches. The study will assess whether attenuated strains of Herpes Simplex Virus type 1 (VC2 and VC2-GMCSF) and an attenuated Vesicular Stomatitis Virus variant (VMG) can reduce psoriasis-like inflammation by modulating local immune responses and decreasing plaque formation.

A mouse model of psoriasis-like skin inflammation will be used to evaluate treatment effects, with disease progression monitored through clinical observations and tissue-based analyses. Findings from this study will help determine whether these attenuated viral platforms can safely and effectively rebalance immune responses in the skin, with potential to inform more targeted psoriasis therapies with fewer systemic side effects.

Risk Assessment and Discussion:

This project presents a moderate biosafety risk associated with the use of attenuated oncolytic viral vectors, including modified strains of HSV-1 and vesicular stomatitis virus (VSV), in both in vitro studies and in vivo mouse tumor models. Although these viral strains are attenuated and designed to reduce pathogenicity, they remain replication-competent and may pose risks of exposure through direct contact, accidental inoculation, or aerosol-generating procedures.

Potential hazards include handling infectious viral materials, cultured tumor cells, and tumor-bearing animals, as well as exposure during injections, sample collection, and other routine manipulations. Additional risks include sharps use, contact with contaminated tissues or surfaces, and handling of chemical reagents and plant extracts during experimental procedures.

These risks are effectively managed under BSL-2/ABSL-2 and BL2-N containment, including the use of biological safety cabinets for aerosol-generating procedures, appropriate PPE, standard microbiological and animal-handling practices, and proper decontamination and waste-disposal procedures.

	With these controls in place, the project is considered to be of moderate risk and appropriately contained. No significant environmental or biosecurity concerns are anticipated.
NIH Guidelines:	Section III-D-4-b
Biosafety Level:	BSL-2, ABSL-2, and BL2-N
Training Requirements:	All personnel, including the PI, involved in this project must complete BSL-2 training in accordance with LSU's Environmental Health and Safety (EHS) and Institutional Biosafety Committee (IBC) requirements. In addition, all staff involved in animal procedures or husbandry must complete LSU's approved animal handling and species-specific training as required by the IACUC. All training must be completed before beginning work and refreshed as required by LSU policies and SOPs
IBC Vote:	**Approved at BSL-2, ABSL-2, and BL2-N pending receipt of modifications**
	Motion made by: Niranjan Baisakh
	Seconded by: Ramanuj Lahiri
	Abstaining: None
	Conflicts of Interest: None

Requested Modifications:

- Section B. Project Description.
  - Procedures and Methods. Please indicate that you will use a final concentration of 10% bleach for a minimum contact time of 30 minutes.
- Section C. Risk Evaluation
  - Biosafety. Please remove information on cancer cells since they are not part of this project. Please indicate that you will use a final concentration of 10% bleach for a minimum of 30 minutes of contact time.
  - Biosecurity. Please update dry heat sterilization to autoclave.
- Section D. Project Units.
  - Item 12. Please change no to yes.
- Section F. Recombinant DNA.
  - DNA/RNA Insertions/Deletions. Item 2. Please add information on the G protein for the Morroton virus. Vectors. Item 4. Selection. Please list antibiotics.
- Section M. Human or Primate Blood, Body Fluids, or Tissues.
  - Containment, Disposal, and Destruction Measures. Please indicate that you plan to use primary and secondary leak-proof containment. Please add the flow cytometry room number.
- Section N. Safety.
  - Biosafety Cabinet. Please confirm certification dates for all BSCs.
  - PPE. Please indicate what type of gloves will be worn.

Reg. #	PI Name	Affiliation of PI	Date Received	Title of Project	Reviewer 1	Reviewer 2
25070 (On Hold)	Jean Christopher Chamcheu	Pathobiological Sciences	04/01/2026	Evaluating the Anti-Tumor Efficacy of Attenuated Vesicular Stomatitis Virus and Herpes Simplex Virus-1 Combined with Garcinia Kola Extracts in Skin and Breast Cancer Mouse Models	Ramanuj Lahiri	Niranjan Baisakh

Project Overview:

This project evaluates novel combination therapies for aggressive cancers, specifically triple-negative breast cancer (TNBC) and melanoma, using two strategies: attenuated oncolytic viral vectors and plant-derived compounds. The study will assess whether extracts from *Garcinia kola*, known for anti-inflammatory and anticancer properties, can enhance the therapeutic effects of attenuated strains of herpes simplex virus-1 (HSV-1) and vesicular stomatitis virus (VSV) in TNBC and melanoma mice models.

In vitro and in vivo studies will be conducted using tumor cell lines and mouse models to evaluate treatment efficacy, including tumor reduction, prevention of relapse, and inhibition of metastasis. Outcomes will focus on tumor progression and immune response to determine the potential of these combination therapies as more targeted and less toxic cancer treatments.

Risk Assessment and Discussion:

This project presents a moderate biosafety risk consistent with research evaluating the potential role of Bovine Leukemia Virus (BLV) in breast cancer using in vitro and in vivo models. The work includes characterization of BLV infection in human breast tissues and mammary epithelial cells, as well as assessment of BLV-associated changes in gene expression and early pro-oncogenic phenotypes.

Potential hazards include handling infectious or BLV-associated materials, human-derived tissues and cells, and conducting laboratory and animal procedures that may involve exposure through sharps, mucous membranes, or aerosol-generating activities. These risks are effectively managed under Biosafety Level 2 (BSL-2), Animal Biosafety Level 2 (ABSL-2), and BL2-N practices, including appropriate PPE, use of a biological safety cabinet, routine decontamination, controlled animal handling, and proper disposal of biohazardous materials.

With these precautions in place, the project is considered moderate risk but appropriately contained under standard BSL-2, ABSL-2, and BL2-N practices. No environmental or security concerns are anticipated.

NIH Guidelines: Section III-D-4-b

Biosafety Level: BSL-2, ABSL-2, and BL2-N

Training Requirements:	All personnel, including the PI, involved in this project must complete BSL-2 training in accordance with LSU's Environmental Health and Safety (EHS) and Institutional Biosafety Committee (IBC) requirements. In addition, all staff involved in animal procedures or husbandry must complete LSU's approved animal handling and species-specific training as required by the IACUC. All training must be completed before beginning work and refreshed as required by LSU policies and SOPs.
IBC Vote:	**Approved at BSL-2, ABSL-2, and BL2-N pending receipt of modifications**
Motion made by:	Ramanuj Lahiri
Seconded by:	Niranjan Baisakh
Abstaining:	None
Conflicts of Interest:	None

Requested Modifications:

- Section B. Project Description.
  - Procedures and Methods. Please indicate that you will use a final concentration of 10% bleach for a minimum contact time of 30 minutes.
- Section C. Risk Evaluation
  - Biosafety. Please indicate that you will use a final concentration of 10% bleach for a minimum of 30 minutes of contact time. Please add a statement on chemical safety, including waste disposal, PPE requirements, animal bedding disposal, chemical fume hood use, and any other relevant safety information.
  - Biosecurity. Please update dry heat sterilization to autoclave.
- Section D. Project Units.
  - Item 12. Please change no to yes.
- Section F. Recombinant DNA.
  - DNA/RNA Insertions/Deletions. Item 2. Please add information on the G protein for the Morroton virus. Vectors. Item 4. Selection. Please list antibiotics.
- Section M. Human or Primate Blood, Body Fluids, or Tissues.
  - Containment, Disposal, and Destruction Measures. Please indicate that you plan to use primary and secondary leak-proof containment. Please add the flow cytometry room number.
- Section N. Safety.
  - Biosafety Cabinet. Please confirm certification dates for all BSCs.
  - PPE. Please indicate what type of gloves will be worn. Please check other and add hair net.

Reg. #	PI Name	Affiliation of PI	Date Received	Title of Project	Reviewer 1	Reviewer 2
26008 (On Hold)	Victoria Coutts	Biological Sciences	02/11/2026	Impacts of Ectoparasites on Parental Feeding Behavior and Offspring Microbiome in Wild Songbirds	Sue Hagius	Sarah Keeton

Project Overview:

This project evaluates how increasing ectoparasite infestations (northern fowl mites) in nest boxes influence parental behavior and offspring development in cavity-nesting birds. Mite levels will be experimentally controlled to assess how parent birds respond to parasite stress and whether they adjust care to support chick survival. Adult birds will be tagged for behavioral monitoring, and nestlings will be assessed for growth, health, and parasite burden, with biological samples collected for laboratory analysis.

Findings from this study will improve understanding of how parasite pressure impacts bird health and reproductive success and may inform future conservation and management strategies.

Risk Assessment and Discussion:

This project presents a moderate biosafety risk associated with field-based research involving wild birds, environmental sampling, and the handling of biological specimens. The work includes exposure to ectoparasites (northern fowl mites) and the collection of blood, fecal material, swabs, and tissues that may contain unknown or zoonotic agents.

Potential hazards include contact with wild animals and associated parasites, handling of biological samples, and the use of sharps during blood collection, all of which pose a risk of percutaneous injury or exposure. Additional risks include transport of samples from the field to the laboratory and the use of chemical reagents (e.g., fixatives and extraction buffers) during downstream processing.

These risks are effectively managed through appropriate PPE, adherence to safe animal handling and sampling procedures, proper sharps disposal, and secure transport and storage of samples. Laboratory work will be conducted under BSL-1 conditions with BSL-2 practices for biological sample handling, including the use of engineering controls where appropriate and standard decontamination procedures.


With these controls in place, the project risk is considered moderate and adequately mitigated. No significant environmental or biosecurity concerns are anticipated.

NIH Guidelines:

Not Applicable

Biosafety Level:	BSL-1 and BSL-2
Training Requirements:	All personnel, including the PI, involved in this project must complete BSL-1 training with BSL-2 practices for biological sample handling, in accordance with LSU's Environmental Health and Safety (EHS) and Institutional Biosafety Committee (IBC) requirements. Personnel conducting fieldwork must also receive appropriate training in wildlife handling, field safety, and sharps use prior to initiating activities. All required training must be completed before beginning work and refreshed as required by LSU policies and SOPs.
IBC Vote:	**Approved at BSL-1 and BSL-2 pending receipt of modifications**
Motion made by:	Sue Hagius
Seconded by:	Sarah Keeton
Abstaining:	None
Conflicts of Interest:	None

Requested Modifications:



Confidential - Not subject to NIH Guidelines

Reg. #	PI Name	Affiliation of PI	Date Received	Title of Project	Reviewer 1	Reviewer 2
26016	David Donze	Biological Sciences	03/05/2026	Interactions Among Chromatin Modifiers in *Saccharomyces cerevisiae*	William Doerrler	Jong Ham

Project Overview:

This project investigates how histone modifications regulate gene expression and interact to influence cellular function. The study focuses on key regulatory genes in yeast, including *RPD3* (a histone deacetylase), *SET1* (a histone methyltransferase), and *SUM1* (a transcriptional repressor), to understand how changes in chromatin structure affect gene silencing and viability.

Using genetic mutations and standard molecular biology approaches, the research examines how alterations in these pathways impact gene regulation, including mechanisms of enhanced gene silencing and synthetic lethality. Findings from this work will improve understanding of epigenetic regulation and chromatin dynamics.

Risk Assessment and Discussion:

This project presents low biosafety risk consistent with routine molecular and genetic studies in *Saccharomyces cerevisiae*, a non-pathogenic laboratory organism. The research involves analysis of histone modification pathways and gene regulation using yeast mutants and standard molecular biology techniques.

Potential hazards are minimal and limited to routine laboratory procedures, including handling non-pathogenic yeast cultures, recombinant DNA constructs, and standard laboratory reagents, with minor risks such as accidental exposure, spills, or sharps-related injury. These risks are effectively managed under Biosafety Level 1 (BSL-1) containment through standard microbiological practices, appropriate PPE, routine surface decontamination, and proper waste disposal.

No human pathogens, viral vectors, or other significant biological hazards are described. With these precautions in place, the project is considered low risk and appropriately contained under standard BSL-1 practices. No environmental or security concerns are anticipated.

NIH Guidelines:	Section III-F-8, Appendix C
Biosafety Level:	BSL-1
Training Requirements:	All personnel, including the PI, involved in this project must complete BSL-1 training in accordance with LSU's Environmental Health and Safety (EHS) and Institutional Biosafety Committee (IBC) requirements. All training must be completed before beginning work and refreshed as required by LSU policies and SOPs.
IBC Vote:	**Approved at BSL-1 pending receipt of modifications.**
Motion made by:	William Doerrler
Seconded by:	Jong Ham
Abstaining:	None
Conflicts of Interest:	None

Requested Modifications:

- Section A. Project Information
  - Personnel. Please list EHS-specific training courses under specific training for all personnel and the PI.
- Section B. Project Description.
  - Procedures and Methods. Please elaborate on procedures and methods. The attached SOP contains information that needs to be included here. Please indicate what work takes place in what room. Please state that you work with E. coli K12 for standard cloning. Please add details on the use of CRISPR, including which genes you plan to modify.
- Section C. Risk Evaluation
  - Biosafety. Please state that you work with the E. coli K12 strain. Please state that PPE will be worn when working in the lab, and that disposable gloves will also be used. Face shields are marked under Section N. Safety—please describe their use here.
  - Biosecurity. Please include undergraduate workers under personnel and add a statement on secure transport between labs.
- Section F. Recombinant DNA
  - NIH Guidelines. Please update to Section III-F-8, Appendix C. Please indicate what various proteins you plan to express in S. cerevisiae.
- Section N. Safety.
  - Sharps. Please describe the use of needles and syringes under Section B. Procedures and Methods. If they are not used, please uncheck here.
  - PPE. Please describe the use of face shields under Section C. Biosafety. If not being used, please uncheck here.

Reg. #	PI Name	Affiliation of PI	Date Received	Title of Project	Reviewer 1	Reviewer 2
26017	Bikram Subedi	Environmental Sciences	03/07/2026	Analysis of Chemical Contaminants Including Drug Residues in Wastewater	William Doerrler	James Bush

Project Overview: Due to insufficient information in the initial submission, the registration was returned to the PI for additional detail and revision before proceeding to full committee review.

Risk Assessment and Discussion: The IBC determined that the application lacked sufficient information to complete a risk assessment; therefore, the registration has been placed "on hold" pending receipt of additional details.

NIH Guidelines: To be determined
Biosafety Level: To be determined
Training Requirements: To be determined

IBC Vote: **No motion was made. The protocol was placed "ON HOLD".**

Motion made by: None
Seconded by: None
Abstaining: None
Conflicts of Interest: None

Requested Modifications:


- Section A. Project Information
  - Buildings. Please update building information to Energy, Coast, and Environment Building
  - Personnel. Please list BSL-2 EHS-specific training courses under specific training for all personnel, including the PI.
- Section B. Project Description.
  - Project Goals. Please update that section to reflect a general overview of the project and the goals. Be sure to include information on what you are testing for and why it is important. Information relating to procedures and methods needs to be removed.

    - Procedures and Methods. Please elaborate on all procedures and methods, including how you collect samples, secure transport, extraction, and downstream processing in the lab. Please indicate what work takes place in what lab and what work takes place inside a BSC. Please describe an autosampler and describe manual sampling techniques. Please add a statement on how hazards from wastewater are addressed, including the use of PPE in the lab and field. Please indicate that leftover samples are decontaminated in a final concentration of 10% bleach for a minimum of 30 minutes before being discarded down the drain.
- Section C. Risk Evaluation
    - Containment Level. Please check BSL-2 and uncheck 'containment level not applicable'.
    - Biosafety. Please describe the use of PPE in the lab versus the field, including when an N95 is required. Please also indicate how feidl PPE is collected and returned to the lab for disposal. Please describe how aerosols are contained during wastewater processing. Please list personnel training and how you address exposure to potential pathogens present in samples.
    - Biosecurity. Please indicate if you keep an inventory of samples and how they are stored. Please also describe the management of that inventory. Please describe secure transport from the field to the lab and describe how solid and liquid biohazardous waste are handled. Please also include a statement on chemical waste.
- Section D. Project Units.
    - Item 7. Please change no to yes and complete the corresponding section.
    - Item 8. Please change yes to no.
- Section N. Safety.
    - Administrative Controls. Disinfection/Decontamination. Please indicate how solid biohazardous waste is handled.
    - Stock Cultures. Please change no to yes and complete the corresponding information, including the room number.
    - PPE. Please describe the use of N95s under Section C. Biosafety. Please check safety glasses/goggles.
    - Other Safety Equipment. Please check spill kit and phone.
- Section O. Medical Surveillance.
    - Because you are handling human waste, bloodborne pathogens training is required. Please have all personnel complete this training and list under specific training in Section A. Personnel.

Reg. #	PI Name	Affiliation of PI	Date Received	Title of Project	Reviewer 1	Reviewer 2
26018	Morgan Kelly	Biological Sciences	03/15/2026	Selection Experiments and Sequencing to Identify Mechanisms of Thermal and Adaption in a Splash Pool Copepod	Jong Ham	Sue Hagius

Project Overview:	This project investigates how marine zooplankton (*Tigriopus californicus*) adapts to heat and changing temperatures. The study will examine several aspects of temperature tolerance, including how much heat the organisms can survive, how flexible they are in responding to temperature changes, and the temperature at which they perform best (e.g., grow and reproduce most efficiently). These experiments will be integrated with physiological assessments and genomic analyses, including transcriptome profiling and whole-genome resequencing, to identify the molecular and genetic mechanisms underlying thermal adaptation. Findings from this work will improve understanding of how organisms respond to environmental stress at both the physiological and genetic levels
Risk Assessment and Discussion:	This project presents low biosafety risk associated with research involving marine zooplankton collected from Pacific coast waters and maintained for laboratory study. Potential hazards are minimal and primarily related to handling field-collected aquatic organisms and associated environmental material, which may contain naturally occurring microorganisms, as well as routine laboratory procedures involving biological samples and standard reagents. Minor risks include accidental exposure, spills, or sharps-related injury. These risks are effectively managed under Biosafety Level 1 (BSL-1) containment through standard laboratory practices, appropriate PPE, routine surface decontamination, and proper waste disposal. No human pathogens, infectious viral vectors, or other significant biological hazards are described. With these precautions in place, the project is considered low risk and appropriately contained under standard BSL-1 practices. No significant environmental or security concerns are anticipated.
NIH Guidelines:	Not Applicable
Biosafety Level:	BSL-1
Training Requirements:	All personnel, including the PI, involved in this project must complete BSL-1 training in accordance with LSU's Environmental Health and Safety (EHS) and Institutional Biosafety Committee (IBC) requirements. All training must be completed before beginning work and refreshed as required by LSU policies and SOPs.
IBC Vote:	**Approved at BSL-1 pending receipt of modifications.** Motion made by: Sue Hagius Seconded by: Jong Ham Abstaining: None Conflicts of Interest: None

Requested Modifications:



Upcoming Meetings:	May 7, 2026 @1:30 pm via Zoom
Adjourned:	3:01 pm